Antivirals for management of herpes zoster including ophthalmicus: A systematic review of high-quality randomized controlled trials

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 255-264

  McDonald, Elissa M ^a   De Kock, Johannes ^b   Ram, Felix S F ^c  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b WHANGAREI HOSPITAL   (New Zealand)

^c MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; FAMCICLOVIR; VALACICLOVIR;

CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALING; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; IMMUNOCOMPETENCE; META ANALYSIS; NAUSEA; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALINE;

EID: 84860317044     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2011     Document Type: Review

References (32)

1. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347:340-346. (Pubitemid 34815357)
2. Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol 2007; 3:82-94. (Pubitemid 46237915)
3. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87:121-129. (Pubitemid 30621444)
4. Bartlett J, Jaanus S. Clinical ocular pharmacology. 5th ed. St Louis, MO: Butterworth Heinemann Elsevier 2008.
5. Chakrabarty A, Tyring SK, Beutner K, Rauser M. Recent clinical experience with famciclovir - a 'third generation' nucleoside prodrug. Antivir Chem Chemother 2004; 15:251-253. (Pubitemid 39452243)
6. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995; 39:2759-2764.
7. Wang LH, Schultz M, Weller S, Smiley ML, Blum MR. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother 1996; 40:80-85. (Pubitemid 26019682)
8. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; 41:Suppl 1:93-96. (Pubitemid 23290491)
9. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:89-96.
10. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546-1553.
11. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107:1507-1511.
12. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9:863-869.
13. Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 2001; 85:576-581. (Pubitemid 32397834)
14. Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995; 45:39-45.
15. Opstelten W, Eekhof J, Neven AK, Verheij T. Treatment of herpes zoster. Can Fam Physician 2008; 54:373-377. (Pubitemid 351413661)
16. Goh CL, Khoo L. A retrospective study on the clinical outcome of herpes zoster in patients treated with acyclovir or valaciclovir vs patients not treated with antiviral. Int J Dermatol 1998; 37:544-546. (Pubitemid 28329052)
17. Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001; 34:138-142. (Pubitemid 32641346)
18. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29:248-253. (Pubitemid 38281215)
19. Shen MC, Lin HH, Lee SS, Chen YS, Chiang PC, Liu YC. Double-blind, randomized, acyclovir-controlled, parallelgroup trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004; 37:75-81. (Pubitemid 38828589)
20. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003; 59:49-56. (Pubitemid 36773890)
21. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1-S26. (Pubitemid 44956795)
22. Review Manager (RevMan). Version 4.3 for Windows. Copenhagen: Nordic Cochrane Centre 2006.
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
24. Higgins J, Green S (Editors). Cochrane handbook for systematic reviews of interventions 4.2.5. Chichester, UK: John Wiley & Sons Ltd 2005.
25. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990; 6:5-30. (Pubitemid 20287159)
26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748.
27. Altman DG, Andersen P. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319:1492-1495.
28. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4:241-246. (Pubitemid 24334158)
29. Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19:47-55. (Pubitemid 40268140)
30. Xu HZ, Mao LE, Luo BG, Zhou SX, Bian ZP. A randomised controlled trial of famciclovir versus acyclovir in the treatment of herpes zoster. Journal of Clinical Dermatology. 2000; 29:288-289.
31. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197 Suppl 2:S228-S236. (Pubitemid 351590176)
32. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; 2:CD006866.